The new Nycomed Executive Committee appointed

25.10.2006Plans for Nycomed’s proposed purchase of ALTANA Pharma AG moved forward today with the announcement of the Executive Committee that will lead the new company upon approval and completion of the deal.

As previously announced, current Nycomed CEO Håkan Björklund will be CEO of the new company, and Hans-Joachim Lohrisch, current ALTANA Pharma President and CEO, will be a member of the board of the combined group and assist Håkan Björklund during the integration period.

“This is a great opportunity to create an outstanding new healthcare company with increased market strength and greater access to new products. With the nomination of the new Executive Committee and other direct reports we have taken the first important step towards the realisation of this,” said Håkan Björklund, Nycomed CEO.

“I have every confidence that this talented and experienced team will have what it takes to shape and drive Nycomed so that it fulfils its true potential and makes a real difference to the needs of patients and healthcare professionals.”

The Executive Committee

The new Executive Committee will comprise the following members and functional areas:

Håkan Björklund, Chief Executive Officer (CEO)

Runar Bjørklund, currently Chief Financial Officer (CFO), Nycomed, will assume the same position in the new company

Charles Depasse, previously Senior Vice President, Operations, Nycomed, will be Executive Vice President, Integration

Alfred Goll, currently Member of the Board of Management, Human Resources, Information and Communication Technology, ALTANA Pharma, will be Executive Vice President, Human Resources

Barthold Piening, currently Corporate Vice President, Operations, ALTANA Pharma, will be Executive Vice President, Product Supply

Otto Schwarz, currently Member of the Board of Management, Business Strategy and Commercial Operations, ALTANA Pharma, will be Executive Vice President, Commercial Operations

Dick Söderberg, currently Senior Vice President, International Marketing, Nycomed, will be Executive Vice President, Marketing

Kerstin Valinder, currently Senior Vice President, Corporate Business Development and Export, Nycomed, will be Executive Vice President, Business Development

Executive Vice President, Research and Development. To be appointed.

An external search is underway to identify a new head of Research and Development (R&D). In the interim, Ulrich Thibaut and Alejandra Mørk, currently responsible for the R&D organisations in ALTANA Pharma and Nycomed respectively, will continue in their current roles and report to Håkan Björklund.

Although the Integration Office is a temporary project organisation, it is represented on the Executive Committee due to its key role in supporting the building of the new organisation.

The combined company will have a considerably larger number of strategic products to support and a broader geographical scope than the current Nycomed and ALTANA Pharma. To secure optimal focus and resource allocation to both Marketing and Sales, they will be two separate functions working in close co-operation.

Marketing will be responsible for product and launch strategies, marketing support and life-cycle management of core products, and will incorporate Market Research, Business Intelligence and Health Economics.

Commercial Operations will be responsible for the new company’s sales presence in its markets including sales through partners. It will execute global strategies for core products and drive strategies for local products. As currently, Nycomed Russia-CIS will report directly to Håkan Björklund.

Business Development will be responsible for business strategy, including mergers and acquisitions, in-licensing and out-licensing.

Other direct reports to the CEO

In addition to the appointment of the new Executive Committee, the following have been assigned responsibility for corporate functions and will also report to Håkan Björklund:

Hans Arvid Danielsson, currently Senior Vice President, Human Resources and Information Systems and Information Technology (IS/IT), Nycomed, will be Senior Vice President, IS/IT

Jostein Davidsen, currently Senior Vice President, Russia-CIS, will assume the same position in the new company

Michael Kuner, currently Corporate Vice President, Legal Affairs, ALTANA Pharma, will be Senior Vice President, Legal

Stig Roswall, currently Senior Vice President, Quality Assurance, Nycomed, will assume the same position in the new company

Head of Corporate Communications. To be appointed.

The new Executive Committee and other direct reports will be effective from the closing of the deal to purchase ALTANA Pharma (expected by the year end). Until then, they will continue in their existing positions and maintain their current responsibilities.

About the ALTANA Pharma acquisition

On 21 September 2006, Nycomed announced that it had reached an agreement to acquire ALTANA Pharma AG, the pharmaceutical business of German-based international pharmaceuticals and chemicals group, ALTANA AG.

Closing of the transaction will be subject to the approval of the shareholders of ALTANA AG and necessary antitrust clearances. Pending the final approvals, closing is expected to take place at the turn of the year. The combined group will continue under the Nycomed corporate brand name and will be headquartered in Zürich, Switzerland.


About Nycomed

Nycomed is a pharmaceutical company dedicated to meeting needs in Europe. The company provides hospital products throughout the region and general practitioner and pharmacy medicines in selected markets.

New products are sourced through licensing agreements with research companies. Here Nycomed provides late-stage clinical development, registration and marketing.

Headquartered in Roskilde, Denmark, the company employs about 3,500 people throughout Europe and Russia-CIS. Nycomed is privately owned and had a 2005 revenue of € 747.5 million.

For more information visit www.nycomed.com


For further information

Håkan Björklund, CEO
Phone: +45 46 77 11 11

Kasper Riis, Communications Director
Phone: +45 46 77 11 15
Mobile: +45 40 95 51 86

 

For further information

Media:
General phone:

+41 44 555 15 10
Beatrix Benz,

phone: +41 44 555 1508
Tobias Cottmann,

phone: +41 44 555 1501

Investors:
Christian B. Seidelin,

phone: +41 44 555 11 04

Related information


English PDF
Danish PDF

Top of page

Takeda Pharma